SEARCH

SEARCH BY CITATION

References

  • 1
    Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93: 230239.
  • 2
    Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? Hepatology 2001; 34: 194203.
  • 3
    Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488495.
  • 4
    Uemoto S, Sugiyama K, Marusawa H et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494499.
  • 5
    Chazouilleres O, Mamish D, Kim M et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142146.
  • 6
    Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 16681674.
  • 7
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 10581061.
  • 8
    Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006; 6: 10771083.
  • 9
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology 2000; 32: 11891195.
  • 10
    Roque-Afonso AM, Feray C, Samuel D et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 9599.
  • 11
    Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213222.
  • 12
    Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 15811586.
  • 13
    Loss GE Jr, Mason AL, Nair S et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003; 9: 12581264.
  • 14
    Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 12561263.
  • 15
    Andreone P, Caraceni P, Grazi GL et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998; 29: 985989.
  • 16
    Reshef R, Sbeit W, Tur-Kaspa R. Lamivudine in the treatment of acute hepatitis B. N Engl J Med 2000; 343: 11231124.
  • 17
    Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 2022.
  • 18
    Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107113.
  • 19
    Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 17141722.
  • 20
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803806.